Federal Patent Court of Switzerland [2024]: Mepha Pharma AG v Bristol-Myers Squibb Holdings Ireland Unlimited Company, O2022_007,
Switzerland
Back This judgment is a part of the following collection(s): 2024 WIPO Intellectual Property Judges ForumDate of JudgmentMarch 5, 2024Issuing AuthorityFederal Patent CourtLevel of the Issuing AuthorityFirst InstanceType of ProcedureJudicial (Civil)Subject MatterPatents (Inventions), Enforcement of IP and Related LawsPlaintiff/AppellantMepha Pharma AGDefendant/RespondentBristol-Myers Squibb Holdings Ireland Unlimited CompanyKeywords
International competence to assess whether a party is entitled to claim priority,
Significance of parallel proceedings,
Interrelation between EPC and national procedural law
Judgment/DecisionEnglishFederal Patent Court of Switzerland [2024]: Mepha Pharma AG v Bristol-Myers Squibb Holdings Ireland Unlimited Company, O2022_007 HTMLAdditional DocumentsEnglish2024 WIPO IP Judges Forum Informal Case Summary – Federal Patent Court of Switzerland [2024]: Mepha Pharma AG v Bristol-Myers Squibb Holdings Ireland Unlimited Company, O2022_007 HTMLRelevant Legislation